Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Lilly Chief Financial Officer Lucas Montarce told Reuters last month the drugmaker is trying to balance its demand-generation activities with its ability to supply more patients. The company last year ...

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.